Switching from Mounjaro to Wegovy: what the data actually says

What did @symoneshops actually say?

She's planning to switch from Mounjaro (tirzepatide) 5mg to Wegovy (semaglutide) after 63 weeks on tirzepatide, and she's nervous about it. Critically, she says she'll be "starting from like the bottom" with Wegovy, implying a dose restart. She's asking her audience for personal experiences before the switch. This is a personal health update, not a medical recommendation, and that framing matters.

To her credit, she's not claiming one drug is better than the other or telling anyone else what to do. She's sharing anxiety about a real clinical decision. That's a reasonable thing to post. The problem is 77,000 viewers absorbing the implicit message that switching between these two drugs is straightforward and something you just do based on vibes and community feedback.

Does the science back up the idea that switching is a meaningful concern?

Yes, actually. The nervousness is clinically justified, even if she doesn't quite articulate why. Tirzepatide and semaglutide are not interchangeable drugs. Tirzepatide is a dual GIP/GLP-1 receptor agonist. Semaglutide is a GLP-1 receptor agonist only. They work through overlapping but distinct mechanisms, and the weight loss data reflects that difference.

The SURMOUNT-1 trial (Jastreboff et al., 2022, NEJM) showed tirzepatide at 15mg achieving mean weight loss of around 20.9% of body weight. The STEP 1 trial (Wilding et al., 2021, NEJM) showed semaglutide 2.4mg achieving around 14.9%. These are not head-to-head comparisons with identical populations, so you can't call it a clean win for tirzepatide, but the signal is consistent across studies. Switching from a dual agonist to a single agonist after over a year is not a trivial decision.

What did she get wrong, or right?

She got the nervousness right. She got the "starting from the bottom" detail right too, in the sense that restarting at a low dose of semaglutide after a year on tirzepatide is standard clinical practice to manage GI side effects. You don't just jump to a therapeutic dose.

What's missing, and this is where 77,000 viewers deserve better, is any mention of why this switch is happening. She gestures at "the current climate," which most viewers will read as a reference to tirzepatide supply shortages or insurance coverage shifts. That context is real and important. Tirzepatide has faced availability issues and formulary changes that have forced patients off it. But saying "current climate" without naming the actual barrier means viewers may think switching is a casual choice rather than a constrained one.

She also doesn't mention that some patients experience meaningful weight regain or increased hunger after stepping down from tirzepatide's dual mechanism. That's not a scare tactic, it's documented in real-world data and worth knowing before week one of the switch.

What should you actually know before switching?

If you're being moved from tirzepatide to semaglutide, here's what the evidence suggests matters. First, expect a dose titration period. Jumping straight to semaglutide 2.4mg from any tirzepatide dose is not how this works clinically. You'll likely start at 0.25mg and titrate over months. Second, some patients report increased appetite and reduced satiety when switching, consistent with losing the GIP receptor activity that tirzepatide provides.

Third, if the reason you're switching is cost or insurance, that's a systemic problem worth documenting, not a personal failure. Fourth, do not let a TikTok comment section replace a conversation with your prescriber about what to expect, how to manage side effects during the transition, and what your weight management goals look like on a different drug. Personal anecdotes from strangers, however well-meaning, are not a substitute for a patient who knows your metabolic history.

The bottom line

@symoneshops is being genuine and appropriately cautious. She's not making false claims. But the framing, asking a mass audience to crowdsource medical transition advice, normalizes a pattern that has real risk. Switching between GLP-1 class drugs involves mechanism differences, titration protocols, and individual response variability that no comment section can account for. The science on tirzepatide versus semaglutide is not settled in a head-to-head sense, but the directional data is consistent enough that this switch deserves a real clinical conversation, not 200 replies from people who may not be on the same dose, have the same history, or the same reason for switching.